Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLIFY JAPAN: Switching from MDI to iGlarLixi in Type 2 Diabetes
jRCT1041210151Completed
- Sponsor
- Sanofi
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in total DTR-QoL score from baseline to Week 24. Started Mar 2022; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1041210151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210151.